RxDoctor Payments Data

Natalie Castillo, NP

Family · Nashville, TNNPI 1427555754

Payments from drug & device makers

$2,113in general payments, 2019–2025

Across 54 payments — averaging $39.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • AstraZeneca$167
  • Bayer$145
  • Boehringer Ingelheim$83
  • Novartis$74
  • Hologic Sales And Service, LLC$67
  • plus $423 from 13 others

What the payments were for

  • Food & beverage$2,08599%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,113 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$27,659
Medicare patients
221
Services billed
362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan162$240,532
JardianceEmpagliflozin108$158,387
EliquisApixaban101$145,124
FarxigaDapagliflozin Propanediol87$111,283
XareltoRivaroxaban13$10,181
Potassium Chloride130$2,619
Bumetanide50$2,531
Torsemide82$2,326
Eplerenone16$1,805
Metoprolol Succinate115$1,731
Spironolactone180$1,205
Atorvastatin Calcium85$874
Carvedilol95$838
Losartan Potassium77$639
Bisoprolol Fumarate15$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$74$240,532162 claims
Boehringer IngelheimJardiance$83$158,387108 claims
PfizerEliquis$26$145,124101 claims
AstraZenecaFarxiga$167$111,28387 claims
Johnson & JohnsonXarelto$64$10,18113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →